Regulatory MSD secures EC approval for Enflonsia to prevent infant RSV infection Pharmaceutical Business ReviewThis approval authorises Enflonsia's marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway.RegulatoryInfectious DiseaseRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaceutical Business Review This approval authorises Enflonsia’s marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway. RegulatoryInfectious DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UCB to purchase Neurona and NRTX-1001 for $1.15bnNext: UCB to purchase Neurona and NRTX-1001 for $1.15bn Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
